Suppr超能文献

肝硬化患者与正常对照人群中常规普萘洛尔与长效普萘洛尔的比较药代动力学研究。

A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls.

作者信息

Watson R G, Bastain W, Larkin K A, Hayes J R, McAinsh J A, Shanks R G

机构信息

Department of Medicine, Queen's University of Belfast, Northern Ireland.

出版信息

Br J Clin Pharmacol. 1987 Oct;24(4):527-35. doi: 10.1111/j.1365-2125.1987.tb03207.x.

Abstract

1 Six male patients with alcoholic cirrhosis and seven normal control subjects were each given 80 mg twice daily of conventional propranolol for 1 week and 160 mg once daily of a long acting preparation (LA) of propranolol for 1 week. 2 Plasma propranolol levels were measured at regular intervals on the first and seventh days of both weeks and also following an acute intravenous infusion of 10 mg propranolol on a separate occasion. 3 After the single intravenous dose the elimination half-life tended to be prolonged in the cirrhotic group (median 7.15 h) compared with controls (median 2.92 h) (P = 0.055). 4 After multiple oral dosing with 80 mg twice daily of conventional propranolol the steady-state plasma concentration (Css), area under the curve (AUC tau), peak concentration (Cmax) and trough concentration (Cmin) were significantly higher in cirrhotic patients and the peak: trough ratio (Cmax/Cmin) was significantly lower than controls. 5 After multiple oral dosing with 160 mg LA once daily Cmin was significantly higher than Cmax/min significantly lower in cirrhotic patients; Css, AUC and Cmax were higher than controls but not statistically different. 6 Within both subject groups the bioavailability of 80 mg twice daily of conventional propranolol tended to be greater than 160 mg LA once daily. Cmax was significantly higher in both groups and Css higher in the cirrhotic group with conventional propranolol. 7 In the cirrhotic group the mean reduction in supine heart rate in the steady state was 31.8% with conventional 80 mg twice daily propranolol and 23.75% with 160 mg LA once daily.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要
  1. 6名酒精性肝硬化男性患者和7名正常对照受试者,每人每天两次服用80毫克常规普萘洛尔,持续1周,然后每天一次服用160毫克长效普萘洛尔制剂(LA),持续1周。2. 在这两周的第一天和第七天定期测量血浆普萘洛尔水平,并且在另一个单独的场合急性静脉输注10毫克普萘洛尔后也进行测量。3. 单次静脉给药后,肝硬化组的消除半衰期(中位数7.15小时)与对照组(中位数2.92小时)相比有延长的趋势(P = 0.055)。4. 肝硬化患者每天两次服用80毫克常规普萘洛尔多次口服给药后,稳态血浆浓度(Css)、曲线下面积(AUC tau)、峰浓度(Cmax)和谷浓度(Cmin)显著更高,且峰谷比(Cmax/Cmin)显著低于对照组。5. 肝硬化患者每天一次服用160毫克LA多次口服给药后,Cmin显著高于对照组,Cmax/min显著低于对照组;Css、AUC和Cmax高于对照组,但无统计学差异。6. 在两个受试者组中,每天两次服用80毫克常规普萘洛尔的生物利用度往往大于每天一次服用160毫克LA。两组的Cmax均显著更高,肝硬化组使用常规普萘洛尔时Css更高。7. 在肝硬化组中,每天两次服用常规80毫克普萘洛尔时,稳态下仰卧心率的平均降低率为31.8%,每天一次服用160毫克LA时为23.75%。(摘要截断于250字)

相似文献

4
Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol.
J Clin Pharmacol. 1987 May-Jun;27(5):390-6. doi: 10.1002/j.1552-4604.1987.tb03036.x.
10
Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.
Eur J Clin Pharmacol. 1987;33(3):315-8. doi: 10.1007/BF00637569.

引用本文的文献

6
Individual variation in first-pass metabolism.首过代谢的个体差异。
Clin Pharmacokinet. 1993 Oct;25(4):300-28. doi: 10.2165/00003088-199325040-00005.
7
Guide to drug dosage in hepatic disease.肝病用药剂量指南。
Clin Pharmacokinet. 1988 Dec;15(6):396-420. doi: 10.2165/00003088-198815060-00004.
8
Safety of propranolol in portal hypertension. Conventional and long acting formulations.
Drugs. 1989;37 Suppl 2:70-3; discussion 74-6. doi: 10.2165/00003495-198900372-00013.

本文引用的文献

7
Cirrhosis, hepatic encephalopathy, and propranolol.肝硬化、肝性脑病与普萘洛尔
Br Med J (Clin Res Ed). 1983 Oct 8;287(6398):1067. doi: 10.1136/bmj.287.6398.1067.
9
Propranolol in decompensated alcoholic cirrhosis.
Lancet. 1982 Nov 6;2(8306):1040-1. doi: 10.1016/s0140-6736(82)90067-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验